Par Health

Executive Summary

Par Health, formed from the merger of Mallinckrodt and Endo in 2019, is a generic pharmaceutical company with over 150 years of combined legacy. It specializes in manufacturing and delivering high-quality generic drugs, active pharmaceutical ingredients (APIs), and sterile injectables through a global network. The company serves critical patient needs with a focus on reliability and integrity. In a competitive generic drug market, Par Health leverages its scale and manufacturing expertise to offer essential medicines, particularly in the sterile injectable segment, where barriers to entry are high. The company operates as a private entity, limiting public financial disclosures, but its foundational strength lies in its diversified product portfolio and global supply chain capabilities. Despite being formed from two historically challenged firms, Par Health has an opportunity to streamline operations and capitalize on the growing demand for cost-effective generic alternatives, especially in hospital and specialty settings.

Upcoming Catalysts (preview)

• Q3 2026FDA Approval of a High-Value Generic Injectable70% success
• Q1 2027Expansion of Manufacturing Capacity in Sterile Injectables80% success
• Q4 2026Strategic Partnership or Licensing Deal for Biosimilars50% success